This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
23 Oct 2019

The talk of the show?

Outsourcing, biologics, generics and patient compliance look set to get tongues wagging at this year's CPHI WW.

Ahead of CPHI Worldwide in Frankfurt next week, Barbara Morgan, Pharmaceutical Business Director at Lubrizol Life Science Health discusses the trends she expects to be the talk of the show.

What do you think will be the major trends and talking points at CPHI Worldwide 2019?

We expect to see a continuation of the growing trend of outsourcing the full spectrum of pharmaceutical services, including commercial manufacturing. Recent figures show that only around one third of manufacturing — whether in the development stages or after commercial launch — is conducted in-house. This year, we have invested in our own commercial manufacturing capabilities with the opening of a new commercial manufacturing facility which is now up and running and recently produced its first set of three registration batches.

The ongoing growth of the biologics market over the past few years will likely be reflected on the show floor, particularly as 2019 has witnessed the FDA releasing guidelines on how biosimilars can achieve an interchangeable status and substitute the reference biologic without a prescriber intervening.

There has also been much discussion this year about the pricing pressures on generics, with regulators, patients and politicians seeking to drive down prices.

In terms of drug development trends, we expect to see an increased focus on long-acting products such as microparticle depots and implants as drug developers seek dosage forms that can aid better patient compliance. This is a topic we are keen to discuss with visitors to our stand.

What is your company hoping to achieve at this year's event?

This year we’re hoping to engage in discussions that center around GMP for clinical trial supply and commercial manufacturing. Lubrizol Life Science Health is currently well known for its focus on complex drug development projects. We’re keen to expand our client base and engage with those who are not yet familiar with our unique capabilities around commercial manufacturing of small batch size products.

What do you most look forward to about CPHI?

I enjoy how well-organized and efficient the CPHI Worldwide event is and the fact that it brings so many people in the industry together, giving you an opportunity to catch up with those clients that you don’t often see in person. It also provides a great environment for meeting new clients and prospects and learning more about the latest trends and talking points in the industry among like-minded peers.

Any presentations/events or news you'd like to tell us about?

This year our big announcement is that we will be changing our name from Particle Sciences to Lubrizol Life Science Health. The name change is an outward sign of our official transition under the Lubrizol Life Science brand umbrella.

As part of Lubrizol Life Science, we can share and draw upon the resources that come with being part of a large corporation, providing customers with greater support and market insights that help them meet their goals.

Related News

  • News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel

    A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to...
  • News Protecting life-saving therapies: CPHI Online Podcast Series

    The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.

  • News 2026 Outsourcing Outlook Update - pharma at a crossroads

    The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ...
  • News Roche maintains German investment commitment whilst rivals scale back

    Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.

  • News Women in Pharma: The History of CPHI Women in Japan

    Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive.
  • News EU drafts deal to end essential medicines shortage

    European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.

  • News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg

    The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th...
  • News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026

    CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.